Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
73.50
+1.39 (1.93%)
May 29, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 97.19 | 85.72 | 89.42 | 188.89 | 34.86 | 15.14 |
Short-Term Investments | 644.28 | 670.81 | 513.67 | 150.38 | 20.85 | 77.99 |
Cash & Short-Term Investments | 741.47 | 756.53 | 603.09 | 339.28 | 55.71 | 93.13 |
Cash Growth | 31.27% | 25.44% | 77.76% | 509.00% | -40.18% | -36.33% |
Accounts Receivable | - | - | - | - | 0.38 | 0.82 |
Other Current Assets | 22.49 | 21.25 | 5.39 | 2.25 | 6.17 | 4.95 |
Total Current Assets | 763.95 | 777.78 | 608.47 | 341.53 | 62.26 | 98.89 |
Net Property, Plant & Equipment | - | - | - | - | 6.65 | 8.36 |
Other Long-Term Assets | - | - | 0.01 | 0.33 | 2.24 | 2.68 |
Total Assets | 763.95 | 777.78 | 608.48 | 341.86 | 71.14 | 109.93 |
Accounts Payable | 5.69 | 8.9 | 0.67 | 0.9 | 0.68 | 3.32 |
Accrued Expenses | 29.16 | 26.95 | 27.71 | 13.11 | 12.84 | 14.03 |
Current Portion of Leases | - | - | - | - | 0.63 | 0.44 |
Unearned Revenue | - | - | - | - | 0.52 | 2.36 |
Other Current Liabilities | 50.31 | 22.83 | 25.68 | 17.97 | - | - |
Total Current Liabilities | 85.16 | 58.69 | 54.06 | 31.98 | 14.66 | 20.14 |
Long-Term Leases | - | - | - | - | 4 | 4.61 |
Other Long-Term Liabilities | 7.98 | 3.86 | 36.62 | 41.31 | 2.18 | 1.23 |
Total Long-Term Liabilities | 7.98 | 3.86 | 36.62 | 41.31 | 6.18 | 5.84 |
Total Liabilities | 93.14 | 62.55 | 90.68 | 73.29 | 20.84 | 25.99 |
Preferred Stock | 155.82 | 155.82 | 155.82 | 184.93 | - | - |
Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,712 | 1,686 | 1,334 | 763.19 | 475.97 | 425.77 |
Accumulated Other Comprehensive Income | -0.77 | 0.87 | 0.18 | 0.3 | -0.05 | -0.02 |
Retained Earnings | -1,197 | -1,128 | -972.43 | -764.41 | -425.62 | -341.81 |
Minority Interest | - | - | - | 84.56 | - | - |
Shareholders' Equity | 670.81 | 715.24 | 517.8 | 184.02 | 50.31 | 83.94 |
Total Liabilities & Equity | 763.95 | 777.78 | 608.48 | 341.86 | 71.14 | 109.93 |
Total Debt | - | 0 | 0 | 0 | 4.63 | 5.04 |
Net Cash (Debt) | 741.47 | 756.53 | 603.09 | 339.28 | 51.08 | 88.08 |
Net Cash Growth | -1.99% | 25.44% | 77.76% | 564.18% | -42.01% | -37.45% |
Net Cash Per Share | 8.60 | 11.81 | 12.82 | 49.19 | 15.15 | 33.49 |
Book Value | 670.81 | 715.24 | 517.8 | 184.02 | 50.31 | 83.94 |
Book Value Per Share | 7.78 | 11.17 | 11.01 | 26.68 | 14.92 | 31.92 |
Tangible Book Value | 670.81 | 715.24 | 517.8 | 184.02 | 50.31 | 83.94 |
Tangible Book Value Per Share | 7.78 | 11.17 | 11.01 | 26.68 | 14.92 | 31.92 |